FDA/CDC

Lymphoma risk prompts FDA recall of Allergan’s textured breast implants

Publish date: July 24, 2019

 

Pages

Recommended Reading

FDA updates breast implant–associated lymphoma cases, risk
MDedge Family Medicine
Five-year survival for non-Hodgkin lymphoma tops 71%
MDedge Family Medicine
Groups release guidelines for CAR T treatment in children
MDedge Family Medicine
Tom Brokaw opens up on surviving multiple myeloma
MDedge Family Medicine
FDA: 246 new reports on breast implant-associated lymphoma
MDedge Family Medicine
Alisertib response rate in PTCL patients was 33%
MDedge Family Medicine
Myeloma therapies raise cardiovascular risks
MDedge Family Medicine
FDA panel leans toward more robust breast implant surveillance
MDedge Family Medicine
FDA panel calls for changes to breast implant rupture screening
MDedge Family Medicine
Powerful breast-implant testimony constrained by limited evidence
MDedge Family Medicine